chr	start	stop	ref	alt	querynator_id	variant_name	variant_aliases	variant_type	variant_clinvar_entries	variant_entrez_id	variant_entrez_name	variant_hgvs_expressions	variant_groups	gene_name	gene_aliases	gene_description	gene_entrez_id	gene_source	mol_profile_name	mol_profile_definition	mol_profile_score	assertion_name	assertion_acmg_codes	assertion_acmg_codes_description	assertion_amp_level	assertion_direction	assertion_type	assertion_description	assertion_disease_name	assertion_disease_doid	assertion_disease_url	assertion_disease_aliases	assertion_phenotypes	assertion_significance	assertion_status	assertion_summary	assertion_therapies_name	assertion_therapies_ncit_id	assertion_therapies_aliases	assertion_therapies_interaction_type	assertion_variant_origin	evidence_name	evidence_description	evidence_disease	evidence_level	evidence_support	evidence_type	evidence_phenotypes	evidence_rating	evidence_significance	evidence_source	evidence_status	evidence_therapies	evidence_therapy_interaction_type
1	11184573	11184573	G	T	4454314	S2215Y	SER2215TYR	Missense Variant	376129	2475	MTOR	ENST00000361445.4:c.6644C>A, NC_000001.10:g.11184573G>T, NM_004958.3:c.6644C>A, NP_004949.1:p.Ser2215Tyr		MTOR	FRAP, FRAP1, FRAP2, MTOR, RAFT1, RAPT1, SKS	mTOR deregulation has been observed in many cancer types. As a part of the PI3K/Akt pathway, there is a broad interest in mTOR biology across cancer types. mTOR inhibition has been investigated for nearly a decade. Everolimus, temsirolimus and zotarolimus are three of the more commonly used mTOR inhibitors used in clinical treatment today, with modest success.	2475	PubMed: Baldo et al., 2008, Curr Cancer Drug Targets, PubMed: Guertin et al., 2007, Cancer Cell, PubMed: Porta et al., 2014, Front Oncol	MTOR S2215Y		2.0																																	
1	11184580	11184580	G	A	7962649	P2213S	PRO2213SER	Missense Variant, Gain Of Function Variant	376358	2475	MTOR	ENST00000361445.4:c.6637C>T, NC_000001.10:g.11184580G>A, NM_004958.3:c.6637C>T, NP_004949.1:p.Pro2213Ser		MTOR	FRAP, FRAP1, FRAP2, MTOR, RAFT1, RAPT1, SKS	mTOR deregulation has been observed in many cancer types. As a part of the PI3K/Akt pathway, there is a broad interest in mTOR biology across cancer types. mTOR inhibition has been investigated for nearly a decade. Everolimus, temsirolimus and zotarolimus are three of the more commonly used mTOR inhibitors used in clinical treatment today, with modest success.	2475	PubMed: Baldo et al., 2008, Curr Cancer Drug Targets, PubMed: Guertin et al., 2007, Cancer Cell, PubMed: Porta et al., 2014, Front Oncol	MTOR P2213S		3.0																																	
1	11187094	11187094	G	T	4231866	F2108L	PHE2108LEU	Missense Variant	NONE FOUND	2475	MTOR	ENST00000361445.4:c.6324C>A, NC_000001.10:g.11187094G>T		MTOR	FRAP, FRAP1, FRAP2, MTOR, RAFT1, RAPT1, SKS	mTOR deregulation has been observed in many cancer types. As a part of the PI3K/Akt pathway, there is a broad interest in mTOR biology across cancer types. mTOR inhibition has been investigated for nearly a decade. Everolimus, temsirolimus and zotarolimus are three of the more commonly used mTOR inhibitors used in clinical treatment today, with modest success.	2475	PubMed: Baldo et al., 2008, Curr Cancer Drug Targets, PubMed: Guertin et al., 2007, Cancer Cell, PubMed: Porta et al., 2014, Front Oncol	MTOR F2108L		16.5																																	
1	11187857	11187857	C	T	3041185	E2014K		Missense Variant	376131	2475	MTOR	NM_004958.4:c.6040G>A, NC_000001.10:g.11187857C>T, NP_004949.1:p.Glu2014Lys		MTOR	FRAP, FRAP1, FRAP2, MTOR, RAFT1, RAPT1, SKS	mTOR deregulation has been observed in many cancer types. As a part of the PI3K/Akt pathway, there is a broad interest in mTOR biology across cancer types. mTOR inhibition has been investigated for nearly a decade. Everolimus, temsirolimus and zotarolimus are three of the more commonly used mTOR inhibitors used in clinical treatment today, with modest success.	2475	PubMed: Baldo et al., 2008, Curr Cancer Drug Targets, PubMed: Guertin et al., 2007, Cancer Cell, PubMed: Porta et al., 2014, Front Oncol	MTOR E2014K AND MTOR E2419K		0.0																																	
1	11188519	11188519	G	A	1437984	H1968Y	HIS1968TYR	Missense Variant, Gain Of Function Variant	376357	2475	MTOR	ENST00000361445.4:c.5902C>T, NC_000001.10:g.11188519G>A, NM_004958.3:c.5902C>T, NP_004949.1:p.His1968Tyr		MTOR	FRAP, FRAP1, FRAP2, MTOR, RAFT1, RAPT1, SKS	mTOR deregulation has been observed in many cancer types. As a part of the PI3K/Akt pathway, there is a broad interest in mTOR biology across cancer types. mTOR inhibition has been investigated for nearly a decade. Everolimus, temsirolimus and zotarolimus are three of the more commonly used mTOR inhibitors used in clinical treatment today, with modest success.	2475	PubMed: Baldo et al., 2008, Curr Cancer Drug Targets, PubMed: Guertin et al., 2007, Cancer Cell, PubMed: Porta et al., 2014, Front Oncol	MTOR H1968Y		3.0																																	
1	11217230	11217230	C	T	1568206	C1483Y	CYS1483TYR	Missense Variant	376453	2475	MTOR	ENST00000361445.4:c.4448G>A, NC_000001.10:g.11217230C>T, NM_004958.3:c.4448G>A, NP_004949.1:p.Cys1483Tyr		MTOR	FRAP, FRAP1, FRAP2, MTOR, RAFT1, RAPT1, SKS	mTOR deregulation has been observed in many cancer types. As a part of the PI3K/Akt pathway, there is a broad interest in mTOR biology across cancer types. mTOR inhibition has been investigated for nearly a decade. Everolimus, temsirolimus and zotarolimus are three of the more commonly used mTOR inhibitors used in clinical treatment today, with modest success.	2475	PubMed: Baldo et al., 2008, Curr Cancer Drug Targets, PubMed: Guertin et al., 2007, Cancer Cell, PubMed: Porta et al., 2014, Front Oncol	MTOR C1483Y		2.0																																	
1	11856378	11856378	G	A	3099550	A222V	RS1801133, C677T, ALA222VAL	Missense Variant	3520	4524	MTHFR	NM_005957.4:c.665C>T, NP_005948.3:p.Ala222Val, ENST00000376592.1:c.665G>A, NC_000001.10:g.11856378G>A		MTHFR	MTHFR		4524		MTHFR A222V		55.0																																	
1	36933434	36933434	G	A	1843490	T618I	THR618ILE	Missense Variant	208339	1441	CSF3R	NP_724781.1:p.Thr618Ile, NM_156039.3:c.1853C>T, ENST00000373103.1:c.1853G>A, NC_000001.10:g.36933434G>A, NC_000001.11:g.36467833G>A		CSF3R	CD114, CSF3R, GCSFR, SCN7		1441		CSF3R T618I		14.0																																	
1	115256528	115256528	T	G	8103256	Q61H	RS121913255, GLN61HIS	Missense Variant	375871	4893	NRAS	NM_002524.4:c.183A>C, NP_002515.1:p.Gln61His, NC_000001.10:g.115256528T>G, ENST00000369535.4:c.183A>C		NRAS	ALPS4, CMNS, KRAS, N-ras, NCMS, NRAS, NRAS1, NS6	Mutations in the RAS family of proteins have frequently been observed across cancer types. The amino acid positions G12, G13 and Q61 account for the overwhelming majority of these mutations. The isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, targeting these RAS mutants has also been very elusive, and has not yet become common practice in the clinic.	4893		NRAS Q61H		5.0																																	
1	115256529	115256529	T	A	4234228	Q61L	GLN61LEU, RS11554290	Missense Variant	375874	4893	NRAS	NP_002515.1:p.Gln61Leu, NC_000001.10:g.115256529T>A, NM_002524.4:c.182A>T, ENST00000369535.4:c.182A>T		NRAS	ALPS4, CMNS, KRAS, N-ras, NCMS, NRAS, NRAS1, NS6	Mutations in the RAS family of proteins have frequently been observed across cancer types. The amino acid positions G12, G13 and Q61 account for the overwhelming majority of these mutations. The isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, targeting these RAS mutants has also been very elusive, and has not yet become common practice in the clinic.	4893		NRAS Q61L	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.	12.5																																	
1	115256529	115256529	T	C	2952738	Q61R	GLN61ARG, RS11554290	Missense Variant	13900	4893	NRAS	NM_002524.4:c.182A>G, NP_002515.1:p.Gln61Arg, NC_000001.10:g.115256529T>C, ENST00000369535.4:c.182A>G		NRAS	ALPS4, CMNS, KRAS, N-ras, NCMS, NRAS, NRAS1, NS6	Mutations in the RAS family of proteins have frequently been observed across cancer types. The amino acid positions G12, G13 and Q61 account for the overwhelming majority of these mutations. The isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, targeting these RAS mutants has also been very elusive, and has not yet become common practice in the clinic.	4893		NRAS Q61R	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.	10.0																																	
1	115256530	115256530	G	T	1787986	Q61K	GLN61LYS, RS121913254	Missense Variant	73058	4893	NRAS	NM_002524.4:c.181C>A, NP_002515.1:p.Gln61Lys, NC_000001.10:g.115256530G>T, ENST00000369535.4:c.181C>A		NRAS	ALPS4, CMNS, KRAS, N-ras, NCMS, NRAS, NRAS1, NS6	Mutations in the RAS family of proteins have frequently been observed across cancer types. The amino acid positions G12, G13 and Q61 account for the overwhelming majority of these mutations. The isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, targeting these RAS mutants has also been very elusive, and has not yet become common practice in the clinic.	4893		NRAS Q61K		24.5																																	
1	115258744	115258744	C	T	5465086	G13D	GLY13ASP, RS121434596	Missense Variant	13901	4893	NRAS	NM_002524.4:c.38G>A, NP_002515.1:p.Gly13Asp, NC_000001.10:g.115258744C>T, ENST00000369535.4:c.38G>A		NRAS	ALPS4, CMNS, KRAS, N-ras, NCMS, NRAS, NRAS1, NS6	Mutations in the RAS family of proteins have frequently been observed across cancer types. The amino acid positions G12, G13 and Q61 account for the overwhelming majority of these mutations. The isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, targeting these RAS mutants has also been very elusive, and has not yet become common practice in the clinic.	4893		NRAS G13D	While the NRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated.	5.0																																	
1	115258745	115258745	C	A	4337967	G13C	RS121434595, GLY13CYS	Missense Variant	40471	4893	NRAS	NM_002524.4:c.37G>T, NP_002515.1:p.Gly13Cys, NC_000001.10:g.115258745C>A, ENST00000369535.4:c.37G>T		NRAS	ALPS4, CMNS, KRAS, N-ras, NCMS, NRAS, NRAS1, NS6	Mutations in the RAS family of proteins have frequently been observed across cancer types. The amino acid positions G12, G13 and Q61 account for the overwhelming majority of these mutations. The isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, targeting these RAS mutants has also been very elusive, and has not yet become common practice in the clinic.	4893		NRAS G13C		0.0																																	
1	115258745	115258745	C	G	7718445	G13R	RS121434595, GLY13ARG	Missense Variant	13899	4893	NRAS	NM_002524.4:c.37G>C, NP_002515.1:p.Gly13Arg, NC_000001.10:g.115258745C>G, ENST00000369535.4:c.37G>C		NRAS	ALPS4, CMNS, KRAS, N-ras, NCMS, NRAS, NRAS1, NS6	Mutations in the RAS family of proteins have frequently been observed across cancer types. The amino acid positions G12, G13 and Q61 account for the overwhelming majority of these mutations. The isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, targeting these RAS mutants has also been very elusive, and has not yet become common practice in the clinic.	4893		NRAS G13R		5.0																																	
1	115258747	115258747	C	A	5160928	G12V	RS121913237	Missense Variant	40470	4893	NRAS	NM_002524.4:c.35G>T, NP_002515.1:p.Gly12Val, NC_000001.10:g.115258747C>A, ENST00000369535.4:c.35G>T		NRAS	ALPS4, CMNS, KRAS, N-ras, NCMS, NRAS, NRAS1, NS6	Mutations in the RAS family of proteins have frequently been observed across cancer types. The amino acid positions G12, G13 and Q61 account for the overwhelming majority of these mutations. The isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, targeting these RAS mutants has also been very elusive, and has not yet become common practice in the clinic.	4893		NRAS G12V		0.0																																	
1	115258747	115258747	C	T	7082271	G12D	RS121913237, GLY12ASP	Missense Variant	39648	4893	NRAS	NM_002524.4:c.35G>A, NP_002515.1:p.Gly12Asp, NC_000001.10:g.115258747C>T, ENST00000369535.4:c.35G>A		NRAS	ALPS4, CMNS, KRAS, N-ras, NCMS, NRAS, NRAS1, NS6	Mutations in the RAS family of proteins have frequently been observed across cancer types. The amino acid positions G12, G13 and Q61 account for the overwhelming majority of these mutations. The isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, targeting these RAS mutants has also been very elusive, and has not yet become common practice in the clinic.	4893		NRAS G12D		7.5																																	
